MTEM / Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Molecular Templates Inc. (MTEM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still tr more_horizontal

AUSTIN, Texas, May 26, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage more_horizontal

Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -56% and 63.99%, respectively, for the quarter ended December 2022. Do the more_horizontal

Molecular Templates (NASDAQ: MTEM ) stock is rocketing higher on Friday after the company got approval from the FDA. That FDA approval has to do with more_horizontal

AUSTIN, Texas, March 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stag more_horizontal

AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage more_horizontal

AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage more_horizontal

AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage more_horizontal